CH EPL (R5)
1.0.0-ci-build - ci-build Switzerland flag

CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ci-build built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: 52042011

identifier: http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MarketingAuthorisationNumber/52042011

subject: MedicinalProductDefinition: extension = Tablet and solvent for rectal suspension,Distale Form der Colitis ulcerosa bei ungenügendem Ansprechen auf oder Kontraindikation für Mesalazin.; identifier = http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-MPID#CH-7601001346451-5204201; combinedPharmaceuticalDoseForm = Tablet and solvent for rectal suspension; indication = Leichte bis mittelschwere Colitis ulcerosa des Rectums sowie des Colon sigmoideum.; legalStatusOfSupply = Medicinal product subject to medical or veterinary prescription (B); additionalMonitoringIndicator = No Warning; pediatricUseIndicator = Authorised for the treatment in children; classification = budesonide,NA KAS art. 12 para. 5 TPLO,Synthetic,Originator product

type: Marketing Authorisation

region: Switzerland

status: valid

statusDate: 1993-06-18

holder: Organization Tillotts Pharma AG

regulator: Organization SMC

Generated Narrative: Organization #holder-Tillotts-Pharma-AG

identifier: LOC Identifier/100005174, GLN Identifier/7601001346451

name: Tillotts Pharma AG

Generated Narrative: Organization #regulator-SMC

identifier: LOC Identifier/100010911, GLN Identifier/7601001398511

name: SMC